Heartcore Capital

Templafy ApS, founded in 2013 and based in Copenhagen, Denmark, provides a comprehensive platform for template and document management solutions. The company specializes in automating business document creation, enabling organizations to produce compliant and on-brand documents efficiently. Its offerings include dynamic personalization, document automation, brand validation, and template governance services. Templafy’s platform integrates seamlessly with existing software, such as Microsoft Office and Salesforce, allowing users to access company templates and streamline content workflows. Catering to various industries, including banking, consulting, education, and legal services, Templafy supports millions of users across over 800 enterprise customers globally. The company has raised significant funding from leading investors to further enhance its innovative document generation capabilities.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, which are serious genetic disorders. Founded on scientific discoveries from the academic work of Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society, Orphazyme collaborates with leading academic institutions across Europe and the United States. The company is actively engaged in biopharmaceutical research and development, and it has entered into a strategic partnership with CombiGene AB to advance its objectives in this field.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, which are serious genetic disorders. Founded on scientific discoveries from the academic work of Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society, Orphazyme collaborates with leading academic institutions across Europe and the United States. The company is actively engaged in biopharmaceutical research and development, and it has entered into a strategic partnership with CombiGene AB to advance its objectives in this field.

Templafy ApS, founded in 2013 and based in Copenhagen, Denmark, provides a comprehensive platform for template and document management solutions. The company specializes in automating business document creation, enabling organizations to produce compliant and on-brand documents efficiently. Its offerings include dynamic personalization, document automation, brand validation, and template governance services. Templafy’s platform integrates seamlessly with existing software, such as Microsoft Office and Salesforce, allowing users to access company templates and streamline content workflows. Catering to various industries, including banking, consulting, education, and legal services, Templafy supports millions of users across over 800 enterprise customers globally. The company has raised significant funding from leading investors to further enhance its innovative document generation capabilities.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, which are serious genetic disorders. Founded on scientific discoveries from the academic work of Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society, Orphazyme collaborates with leading academic institutions across Europe and the United States. The company is actively engaged in biopharmaceutical research and development, and it has entered into a strategic partnership with CombiGene AB to advance its objectives in this field.

Templafy ApS, founded in 2013 and based in Copenhagen, Denmark, provides a comprehensive platform for template and document management solutions. The company specializes in automating business document creation, enabling organizations to produce compliant and on-brand documents efficiently. Its offerings include dynamic personalization, document automation, brand validation, and template governance services. Templafy’s platform integrates seamlessly with existing software, such as Microsoft Office and Salesforce, allowing users to access company templates and streamline content workflows. Catering to various industries, including banking, consulting, education, and legal services, Templafy supports millions of users across over 800 enterprise customers globally. The company has raised significant funding from leading investors to further enhance its innovative document generation capabilities.

Mofibo started in Copenhagen (2013) as one of the world’s first book subscription services. We are currently in three countries and will be expanding into more countries within the next 12 months. Our overall goal is to transform the way millions of people interact with books, through using a data-driven and customer centric approach to fundamentally change the reading experience crosses multiple countries.

Adenium Biotech ApS is a Danish biopharmaceutical company founded in 2011 and based in Copenhagen. The company specializes in the development and commercialization of antibiotics aimed at treating multi-drug resistant bacterial infections, particularly those acquired in hospital settings. Its primary focus includes complicated urinary tract infections and hospital or ventilator-acquired pneumonia, which are often caused by resistant Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Adenium Biotech's lead product, Arenicin, is a non-hemolytic antimicrobial peptide derived from lugworms, demonstrating strong efficacy against Gram-negative pathogens. The company operates as a semi-virtual biotech entity, supported by a team of experts and an international scientific advisory board, with the goal of advancing the Arenicin program through clinical development and regulatory filing.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, which are serious genetic disorders. Founded on scientific discoveries from the academic work of Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society, Orphazyme collaborates with leading academic institutions across Europe and the United States. The company is actively engaged in biopharmaceutical research and development, and it has entered into a strategic partnership with CombiGene AB to advance its objectives in this field.